The life and times of ivermectin - A success story

Nature Reviews Microbiology

Volumn 2, Issue 12, 2004, Pages 984-989

  Õmura, Satoshi ^a   Crump, Andy ^b  

^a KITASATO INSTITUTE   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ABAMECTIN; ALBENDAZOLE; ANTELMYCIN; ANTHELMINTIC AGENT; ANTHELVENCIN; ANTIBIOTIC G 418; ASPICULOMYCIN; AVERMECTIN A1 A; AVERMECTIN A1 B; AVERMECTIN A2 A; AVERMECTIN A2 B; AVERMECTIN B1 A; AVERMECTIN B1 B; AVERMECTIN B2 A; AVERMECTIN B2 B; AVERMECTIN DERIVATIVE; AXENOMYCIN DERIVATIVE; BENZIMIDAZOLE; DESTOMYCIN DERIVATIVE; DIETHYLCARBAMAZINE; HYGROMYCIN B; IVERMECTIN; LEVAMISOLE; MILBEMYCIN DERIVATIVE; PAROMOMYCIN; S 151; SURAMIN; THIAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTHELMINTIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BLINDNESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EDEMA; EYE INFLAMMATION; FEVER; FILARIASIS; GOVERNMENT; HUMAN; MICROFILARIASIS; NONHUMAN; ONCHOCERCIASIS; PAIN; PRIORITY JOURNAL; PRURITUS; STRUCTURE ACTIVITY RELATION; VETERINARY MEDICINE;

AFRICA; AMERICAS; ANIMALS; ANTHELMINTICS; COMMUNITY NETWORKS; COSTS AND COST ANALYSIS; ELEPHANTIASIS, FILARIAL; HUMANS; IVERMECTIN; LIFE CYCLE STAGES; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; STREPTOMYCES;

EID: 9444230640     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1048     Document Type: Article

References (53)

1. Õmura, S. Philosophy of new drug discovery. Microbiol. Rev. 50, 259-279 (1986).
2. Campbell, W. C. in Inventive Minds (eds Weber, R. J. & Perkins, D. N.) Chapter 11, 192-214 (Oxford Univ. Press, New York, 1992).
3. Burg, R. W. & Stapley, E. O. in Ivermectin and Abamectin (ed. Campbell, W. C.) 24-32 (Springer, New York, 1989).
4. Takahashi, Y. et al. Streptomyces avermectinius sp. nov., an avermectin-producing strain. Int. J. Syst. Evol. Microbiol. 52, 2163-2168 (2002).
5. Burg, R. W. et al. Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation. Antimicrob. Agents Chemother. 15, 361-367 (1979).
6. Miller, T. W. Avermectins, new family of potent anthelmintic, agents: isolation and chromatographic properties. Antimicrob. Agents Chemother. 15, 368-371 (1979).
7. 1A component. Antimicrob. Agents Chemother. 15, 372-378 (1979).
8. Sunazuka, T. et al. in Macrolide Antibiotics - Chemistry Biology and Practice 2nd ed. (ed. S. Õmura) 99-180 (Academic Press, 2002).
9. Chabala, J. C. et al. Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23, 1134-1136 (1980).
10. Taylor, H. R. & Greene, B. M. The status of ivermectin in the treatment of human onchocerciasis. Am. J. Trop. Med. Hyg. 41, 460-466 (1989).
11. Ömura, S. et al. Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc. Natl Acad. Sci. USA 98 12215-12220 (2001).
12. Ikeda, H. et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nature Biotechnol. 21, 526-531 (2003).
13. Ömura, S. in Macrolide Antibiotics - Chemistry Biology and Practice 2nd edn (ed. Omura, S.) 571-576 (Academic Press, 2002).
14. 1a on insect muscle. Br. J. Pharmacol. 85, 395-401 (1985).
15. Geary, T. G. et al. Haemonchus contortus: ivermectin-induced paralysis of the pharynx. Exp. Parasitol. 77 88-96 (1993).
16. 1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc. Natl Acad. Sci. USA 76, 2062-2066 (1979).
17. 1a Neuropharmacology 22, 89-96 (1983).
18. Turner, M. & Schaeffer J. M. in Ivermectin and Abamectinn (ed. Campbell, W. C.) 73-88 (Springer, New York, 1989).
19. TDR. Twelfth Programme Report, Tropical Disease Research: progress 1975-94, highlights 1993-94. WHO, Geneva, 1995).
20. Thylefors, B. Eliminating onchocerciasis as a public health problem. Trop. Med. Int. Health 9, A1-A3 (2004).
21. Aziz, M. A. et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 2, 171-173 (1982).
22. Aziz, M. A. et al. Ivermectin in onchocerciasis. Lancet 2, 1456-1457 (1982).
23. White, A. T. et al. Controlled tried and dose-finding study of ivermectin for treatment of infectious diseases. J. Infect. Dis. 156, 463-470 (1987).
24. Greene, B. M. et al. Single dose therapy with ivermectin for onchocerciasis. Trans. Assoc. Am. Physicians 100 131-138 (1987).
25. Newland, H. S. et al. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement. Br. J. Opthalmol. 72, 561-569 (1988).
26. Remme, J. H. F. et al. Large-scale ivermectin distribution and its epidemiological consequences. Acta Leiden. 59, 177-191 (1990).
27. Duke, B. O. L. et al. Effects of multiple monthly doses of ivermectin on adult Onchocerca volvolus. Am. J. Trop. Med. Hyg. 43, 657-664 (1990).
28. Campbell, W. C. et al. Ivermectin: a potent new antiparasitic agent. Science 221, 823-828 (1983).
29. Whitworth, J. A. G. et al. Clinical and parasitological response after up to 6.5 years of ivermectin treatment for onchocerciasis. Trop. Med. Int. Health 1, 786-793 (1992).
30. Aley, E. S. et al. The impact of five years of annual ivermectin treatment on microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans. R. Soc. Top. Mod. Hyg. 88, 581-584 (1994).
31. Kennedy, M. H. et al. The effect of five years of annual treatment with ivermectin (Mectizan®) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann. Trop. Med. Parasitol. 49, 804-811 (2002).
32. Whitworth, J. A. G. et al. A community trial of ivermectin for onchocerciasis in Sierra Leone; clinical and parasitological response to four doses given at six-monthly intervals. Trans. R. Soc. Trop. Med. Hyg. 86, 277-280 (1996).
33. Duke, B. O. L. et al. Effects of three-month doses of ivermectin on adult Onchocerca volvulus. Am. J. Trop. Med. Hyg. 46, 189-194 (1992).
34. Taylor, H. R. et al. Comparison of the treatment of ocular onchocerciaisis with ivermectin and diethylcarbamazine. Arch. Opthalmol. 104, 863-870 (1986).
35. Pacqué, M. et al. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy and acceptability of yearly treatment. J. Infect. Dis. 163, 381-385 (1991).
36. Chijioke, C. P. & Okonkwo, P. Adverse events following mass ivermectin therapy for onchocerciasis. Trans. R. Soc. Top. Med. Hyg. 86, 284-286 (1992).
37. De Sole, G. et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull. World Health Organ. 67, 707-719 (1989).
38. Gardon, J. et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350, 18-22 (1997).
39. Twum-Danso, N. A. Y. Serious adverse events following treatment with ivermectin for onchocerciais control: a review of reported cases. Filaria J. 2 (Suppl.), S3-S13 (2003).
40. WHO. Strategies for ivermectin distribution through primary health care systems. WHO/PBL/91. 24. (WHO, Geneva, 1991).
41. Mectizan Donation Programme. Newsletter of the Mectizan Donation Programme. [online], http://www.mectizan.org/mpn33/mpnhtml336.htm (2004).
42. Waters, H. R. et al. Economic evaluation of Mectizan distribution. Trop. Med. Int. Health 9, A16-A25 (2004).
43. Burnham, G. & Mebrahtu, T The delivery of ivermectin (Mectizan). Trop. Mod. Int. Health 9, A26-A44 (2004).
44. Onwujekwe, O. et al. Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis endemic communilips in Nigeria. Trop. Med. Int. Health 3, 802-808 (1998).
45. Onwujekwe, O. et al. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy 62, 31-51 (2002).
46. Addis, D. G. et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children, Lancet 350, 480-484 (1997).
47. Njoo, FL. et al. Concurrent parastic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment. Am. J. Trop. Med. Hyg. 48, 652-657 (1993).
48. Stephenson, L. S. Optimising the benefits of anthelmintic treatment in children. Paediatr. Drugs 3, 495-508 (2001).
49. Dunne, C. L. et al. A field study of the effects of ivermectin on ectoparasites of man. Trans. R. Soc. Trop. Med. Hyg. 85, 550-551 (1991).
50. Blackhall, W. J. et al. Selection at a P-glycoprotein gene in ivermectin and moxidectin-selected strains of Haemonchus contortus. Mol. Biochem. Parasitol. 95, 193-201 (1998).
51. Kwa, M. S. et al. Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus. Int. J. Parasitol. 28, 1235-1240 (1998).
52. Eckholm, E. Conquering an ancient scourge; river blindness. New York Times Magazine, 20-27 (Jan 8, 1989).
53. Ikeda, H. & Õmura, S. in Macrolide Antibiotics (ed. Õmura, S.) 287-326 (Academic Press, San Diego, 2002).